User: Guest

  



DOMAIN EXPERT ENGAGEMENTS

Number of executives repeatedly engaged by snail & email outreach*

POOL + OUTREACH

11338

Interactions with Platform & by Email *

INTERACTIONS

1361

Unique # Participated *

PARTICIPANTS

340

Responses Validated *

VALIDATIONS

37

* Platform engagements are dynamic. Stats are published quarterly.


  •  CODE

  •  PAGES

  •  DATE

  •  PRICE

    $

  •  DATA EXHIBITS

    125


TABLE OF CONTENTS


   Pages :    | $

   Study Reliability and Reporting Limitations.....I-1  
   Disclaimers.....I-2
Data Interpretation & Reporting Level.....I-2
  
   Quantitative Techniques & Analytics.....I-3
Product Definitions and Scope of Study.....I-3
  
   Penicillin.....I-4
Cephalosporins.....I-4
Macrolides.....I-4
Quinolones.....I-4
Carbapenems.....I-4
Other Antibiotics.....I-4
Aminoglycosides.....I-4
  
   Tetracyclines.....I-5
Sulfonamides.....I-5
Mupirocin.....I-5
Glycopeptides.....I-5
Synercid.....I-5
  
   Oxazolidinones.....I-6
Linezolid.....I-6
  
   Antibiotic Resistance and Generic Competition to Impact Long Term Growth.....II-7
New Regulations Guiding Usage of Drugs to Drive Growth.....II-7
Current & Future Analysis.....II-7
2$200
   Anti-Bacterials Segment Drives Global Anti- Infectives Market.....II-9
Antibiotic Resistance – A Primary Growth Inhibitor.....II-9
Antibiotic-Resistant Bacteria by Type.....II-9
1$100
   Patent Expiries Commoditize Antibiotics.....II-10
Patent Expiries of Leading Drugs in the Recent Past, Current, and Future (2000
  –2013).....II-10
Anti-MRSA Antibiotics Find Their Way.....II-10
1$100
   Table 1: World MRSA Treatments (2007 & 2008) : Percentage Share Breakdown by Leading Antibiotic Drugs - Vancomycin, Zyvox, Cubicin and Tygacil (includes corresponding Graph/Chart).....II-11
Key Antibiotics in Pipeline.....II-11
1$350
   Highly Competitive Market.....II-12
Table 2: Leading Players in the Worldwide Antibiotics Market (2008): Percentage Breakdown by Value Sales for Pfizer, GlaxoSmithkline, Sanofi-aventis, Johnson & Johnson, Bayer, Abbott, Wyeth, and Others (includes corresponding Graph/Chart).....II-12
1$350
   GlaxoSmithKline – The Undisputed Leader of Penicillin Market.....II-13
Table 3: Worldwide Leading Antibiotics within Penicillin Class (2005 & 2006): Percentage Breakdown by Value for Augmentin, Zosyn/ Tazocin, Amoxil, and Others (includes corresponding Graph/Chart).....II-13
1$350
   GlaxoSmithKline Leads Cephalosporin Market.....II-14
Table 4: Worldwide Leading Antibiotics within Cephalosporin Class (2005 & 2006): Percentage Breakdown by Value for Rocephin, Ceftin/Zinnat, Flomox, Fortum/Fortaz, Cefzil, Cefzon, Flumarin, and Others (includes corresponding Graph/Chart).....II-14
1$350
   Pfizer Dominates Macrolides Market.....II-15
Table 5: Worldwide Leading Antibiotics within Macrolide Class (2005 & 2006): Percentage Breakdown by Value for Zithromax, Klaricid/Biaxin, Ketek, and Others (includes corresponding Graph/Chart).....II-15
1$350
   Levaquin/Tavanic – The Most Preferred Quinolone Antibiotic.....II-16
Table 6: Worldwide Leading Antibiotics within Quinolone Class (2005 & 2006): Percentage Breakdown by Value for Levaquin/Tavanic, Avelox, Ciprobay/Ciproxin, Cravid, and Others (includes corresponding Graph/Chart).....II-16
1$350
   Merck Rules Carbapenems Market.....II-17
Table 7: Worldwide Leading Antibiotics within Carbapenem Class (2005 & 2006): Percentage Breakdown by Value for Primaxin, Merrem, Invanz, and Others (includes corresponding Graph/Chart).....II-17
1$350
   Antibiotics – An Introduction.....II-18
Antibiotic Resistance.....II-18
1$100
   ?–Lactams.....II-191$100
   Classification of Antibiotics.....II-20
Key Milestones in Antibiotic Development.....II-20
Antibiotic Types.....II-20
Penicillin.....II-20
History.....II-20
1$100
   About the Drug.....II-21
Cephalosporins.....II-21
Treatment.....II-21
Effects of the Drug.....II-21
1$100
   Macrolides.....II-22
Treatment.....II-22
Quinolones.....II-22
1$100
   Table 8: Leading Global Ciprofloxacin Brands: (2006-2008) (includes corresponding Graph/Chart).....II-23
Carbapenems.....II-23
Other Antibiotics.....II-23
Aminoglycosides.....II-23
1$350
   Treatment.....II-24
Effects of the Drug.....II-24
Tetracyclines.....II-24
Treatment.....II-24
1$100
   Effects of the Drug.....II-25
Sulfonamides.....II-25
1$100
   Treatment.....II-26
Effects of the Drug.....II-26
Mupirocin.....II-26
Glycopeptides.....II-26
1$100
   Synercid.....II-27
Oxazolidinones.....II-27
Linezolid.....II-27
1$100
   New Design for Monitoring Toxin Delivery Activity of Pathogenic Bacteria.....II-28
Cephalosporins Effective when Compared to Penicillin.....II-28
FDA Bans Baytril Antibiotic for Chickens.....II-28
Erythromycin Along with Some Specific Drugs Increase Risk of Sudden Death.....II-28
1$100
   Rise in Usage of Quinolones for Urinary Tract Infections Leads to Drug
  Resistance.....II-29
Polyphor Discovers POL7080 - New Antibiotic Against Gram-Negative Bacteria.....II-29
1$100
   MiddleBrook Obtains NDA Approval for MOXATAG™.....II-30
J&JPRD Seeks FDA Approval for Doripenem Antibiotic.....II-30
J&JPRD Seeks FDA Approval for Investigational Antibiotic, Ceftobiprole.....II-30
GSK Receives Approval for ALTARGO® in Europe.....II-30
1$100
   APL Receives FDA Approval for Cefpodoxime Proxetil.....II-31
Cubist Receives Approval to Market CUBICIN in Canada.....II-31
Cubist Obtains Approval to Market CUBICIN for Added Indications in EU.....II-31
Cubist Gains Approval for CUBICIN in Taiwan and South Korea.....II-31
Cethromycin Achieves FDA’s Orphan Drug Designation.....II-31
1$100
   FDA Approves Wockhardt’s Cefotaxime Injection.....II-32
FDA Approves Doxycycline Tablets.....II-32
FDA Approves Clarithromycin.....II-32
FDA Approves Doxycycline Tablets For The US Market.....II-32
Johnson & Johnson Applies Doripenem For FDA Approval.....II-32
FDA Certifies Antibioticos do Brasil’s Plant.....II-32
FDA Certifies ANDA For Cefdinir Capsules.....II-32
1$100
   US FDA Approves Teva’s Cefprozil Tablets.....II-33
FDA Certifies ANDA for Cephalexin Capsules.....II-33
American Pharmaceutical Partners Receives FDA Approvals for Ceftriaxone for Injection,
  USP.....II-33
Advancis’s Keflex Receives FDA Approval.....II-33
Wockhardt Gains Marketing Approval for Cefuroxime axetil in the US.....II-33
1$100
   Wyeth’s Mylotarq Receives Government’s Approval.....II-34
FDA Approves Generic Version of Zithromax.....II-34
Pfizer Wins FDA Approval for Zmax™.....II-34
Venus Remedies Files Second PCT for New Cephalosporins.....II-34
1$100
   Falcon Gains US FDA Approval for its Generic Anti-Infective Solution.....II-35
Cadilla Receives FDA Approval to Market Clindamycin.....II-35
1$100
   DSM Opens Eco-friendly Antibiotics Plant ZOR-f, in the Netherlands.....II-36
Daiichi Leverages Ranbaxy’s Network to Market Tavanic in South Africa and
  Romania.....II-36
Pfizer Acquires Wyeth.....II-36
Durata Therapeutics Acquires Pfizer’s Vicuron Pharmaceuticals.....II-36
1$100
   Cubist Completes Acquisition of Calixa Therapeutics.....II-37
AstraZeneca to Acquire Novexel.....II-37
Tianyin and Sichuan Mingxin to Establish an Antibiotic Joint Venture.....II-37
1$100
   Pfizer and Aurobindo Pharma Ink Agreement for Producing Off Patent Drugs.....II-38
BMP Sunstone to Acquire Majority Stake in Zhangjiakou Shengda.....II-38
Novartis to Take Over Protez Pharmaceuticals.....II-38
3i to Buy Alpharma Unit.....II-38
1$100
   NCPC to Acquire Stake in DSM’s Antibiotics Division.....II-39
ULL Establishes New Antibiotics Unit in Himachal Pradesh.....II-39
Biocat to Expand Presence in the Indian Market.....II-39
PRWT Acquires Cherokee Chemical Unit from Merck.....II-39
CSPC Joins Hands with Indonesian Firms.....II-39
1$100
   Nisshin-Kyorin to Merge with Kyorin Pharmaceutical.....II-40
Schering-Plough Acquires Organon BioSciences.....II-40
GSK & Anacor Partner for Boron Chemistry-Based Antibiotics and Antivirals.....II-40
1$100
   Iroko Bags Canadian Rights to Vancocin®.....II-41
Cubist Licenses CUBICIN Rights to Merck.....II-41
Sagent Partners with Astral to Develop Injectable Antibiotics.....II-41
MR Healthcare to Manufacture New Antibiotics & Medicines.....II-41
Livzon Synthetic to Acquire Antibiotic Intermediate from Jiaozuo.....II-41
1$100
   C&O Pharmaceutical to Distribute Meiact in China.....II-42
Bioton Signs Deal to Market Antibiotics in Russia.....II-42
Toyama Gains Marketing Approval for Geninax® in Japan.....II-42
Forest Laboratories Acquires Cerexa.....II-42
Oscient Modifies Licensing Agreement With LG Life Sciences.....II-42
Orchid Sign Licensing & Distribution Pact With Actavis.....II-42
1$100
   Forest Laboratories Revokes Partnership With Replidyne.....II-43
SRI and Blanca Collaborate To Develop & Test Carbacephem.....II-43
AstraZeneca To Expand Research Center for Antibiotics.....II-43
Jade Pharmaceutical Begins Levofloxacin’s Production in China.....II-43
1$100
   Reyoung To Start Antibiotic Production At New Facility.....II-44
Toyama Begins T-705 Clinical Trials.....II-44
SmPC For Sanofi-Aventis’ Ketek® Updated.....II-44
Lupin Receives Approval for Cefpodoxime Proxetil Antiobiotic Tablets in France.....II-44
Antibiotice Plans To Infuse Funds For Antibiotics Production.....II-44
UAE Approves Pfizer’s Zithromax SD.....II-44
1$100
   Janssen-Cilag Launches Doribax™ - New Carbapenem Antibiotic.....II-45
MIT Scientists Develop a New Antibiotic, Rhodostreptomycin.....II-45
Watson Pharma Introduces Biaxin XL’s Generic Version.....II-45
1$100
   Toyama Launches New Garenoxacin Quinolone Antibiotic.....II-46
Wockhardt to Introduce Cefprozil in the US.....II-46
MSD India Launches Invanza in India.....II-46
Orchid Chemicals to Introduce Three New Drugs in the US.....II-46
1$100
   DUSA Pharmaceuticals Releases ClindaReach™.....II-47
Mylan Releases Cipro’s Generic Version.....II-47
Macrolide Antibiotic Developed In the US.....II-47
University of Michigan Devises NMR Spectroscopy For Antibiotics.....II-47
Glycopeptide-Cephalosporin Antibiotics Developed in the US.....II-47
Neosil Tests NEO 101 Antibiotic.....II-47
New Antibiotic Developed By Canadian Inventors.....II-47
1$100
   Abbott Canada Releases FACTIVE® Antibiotic Tablets In Canada.....II-48
Penicillin Binding Protein Found In Japan.....II-48
Venus Remedies Releases Mucomelt-Forte.....II-48
1$100
   Abbott Laboratories (USA).....II-49
Astellas Pharma, Inc. (Japan).....II-49
Bayer HealthCare AG (Germany).....II-49
1$100
   Bristol-Myers Squibb Co. (USA).....II-50
Cubist Pharmaceuticals, Inc. (USA).....II-50
1$100
   Daiichi Sankyo Company, Limited (Japan).....II-51
Eli Lilly and Co. (USA).....II-51
1$100
   GlaxoSmithKline Plc (UK).....II-52
Johnson & Johnson (USA).....II-52
1$100
   Kyorin Pharmaceutical Co., Ltd. (Japan).....II-53
LG Life Sciences Limited (Korea).....II-53
1$100
   MiddleBrook™ Pharmaceuticals, Inc. (USA).....II-541$100
   Novartis AG (Switzerland).....II-55
Pfizer Inc. (USA).....II-55
1$100
   Pliva d.d. (Croatia).....II-56
Roche (Switzerland).....II-56
1$100
   Sanofi-Aventis SA (France).....II-57
Takeda Pharmaceutical Company, Ltd. (Japan).....II-57
Toyama Chemical Co., Ltd. (Japan).....II-57
2$125
   Table 9: World Recent Past, Current & Future Analysis for Antibiotics by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).....II-591$350
   Table 10: World Historic Review for Antibiotics by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2006 (includes corresponding Graph/Chart).....II-601$350
   Table 11: World 11-Year Perspective for Antibiotics by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets for Years 2005, 2010 & 2015 (includes corresponding Graph/Chart).....II-611$350
   Table 12: World Recent Past, Current & Future Analysis for Penicillin by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).....II-621$350
   Table 13: World Historic Review for Penicillin by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2006 (includes corresponding Graph/Chart).....II-631$350
   Table 14: World 11-Year Perspective for Penicillin by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets for Years 2005, 2010 & 2015 (includes corresponding Graph/Chart).....II-641$350
   Table 15: World Recent Past, Current & Future Analysis for Cephalosporin by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).....II-651$350
   Table 16: World Historic Review for Cephalosporin by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2006 (includes corresponding Graph/Chart).....II-661$350
   Table 17: World 11-Year Perspective for Cephalosporin by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets for Years 2005, 2010 & 2015 (includes corresponding Graph/Chart).....II-671$350
   Table 18: World Recent Past, Current & Future Analysis for Macrolides by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).....II-681$350
   Table 19: World Historic Review for Macrolides by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2006 (includes corresponding Graph/Chart).....II-691$350
   Table 20: World 11-Year Perspective for Macrolides by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets for Years 2005, 2010 & 2015 (includes corresponding Graph/Chart).....II-701$350
   Table 21: World Recent Past, Current & Future Analysis for Quinolones by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).....II-711$350
   Table 22: World Historic Review for Quinolones by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2006 (includes corresponding Graph/Chart).....II-721$350
   Table 23: World 11-Year Perspective for Quinolones by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets for Years 2005, 2010 & 2015 (includes corresponding Graph/Chart).....II-731$350
   Table 24: World Recent Past, Current & Future Analysis for Carbapenems by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).....II-741$350
   Table 25: World Historic Review for Carbapenems by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2006 (includes corresponding Graph/Chart).....II-751$350
   Table 26: World 11-Year Perspective for Carbapenems by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets for Years 2005, 2010 & 2015 (includes corresponding Graph/Chart).....II-761$350
   Table 27: World Recent Past, Current & Future Analysis for Other Antibiotics by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).....II-771$350
   Table 28: World Historic Review for Other Antibiotics by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2006 (includes corresponding Graph/Chart).....II-781$350
   Table 29: World 11-Year Perspective for Other Antibiotics by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets for Years 2005, 2010 & 2015 (includes corresponding Graph/Chart).....II-791$350
   A. Market Analysis.....II-80
Current and Future Analysis.....II-80
Antibiotics Approved Between 2000 and 2005 in the United States.....II-80
1$100
   Competition.....II-81
Table 30: Leading Players in the US Antibiotics Market (2008): Percentage Breakdown by Value Sales for Pfizer, Johnson & Johnson, GlaxoSmithKline, Abbott, and Others (includes corresponding Graph/Chart).....II-81
Key Players.....II-81
1$350
   B. Market Analytics.....II-82
Table 31: US Recent Past, Current & Future Analysis for Antibiotics by Product Segment - Penicillin, Cephalosporin, Macrolides, Quinolones, Carbapenems and Other Antibiotics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).....II-82
1$350
   Table 32: US Historic Review for Antibiotics by Product Segment - Penicillin, Cephalosporin, Macrolides, Quinolones, Carbapenems and Other Antibiotics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2006 (includes corresponding Graph/Chart).....II-831$350
   Table 33: US 11-Year Perspective for Antibiotics by Product Segment - Percentage Breakdown of Dollar Sales for Penicillin, Cephalosporin, Macrolides, Quinolones, Carbapenems and Other Antibiotics Markets for Years 2005, 2010 & 2015 (includes corresponding Graph/Chart).....II-841$350
   A. Market Analysis.....II-85
Current And Future Analysis.....II-85
1$100
   B. Market Analytics.....II-86
Table 34: Canadian Recent Past, Current & Future Analysis for Antibiotics by Product Segment - Penicillin, Cephalosporin, Macrolides, Quinolones, Carbapenems and Other Antibiotics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).....II-86
1$350
   Table 35: Canadian Historic Review for Antibiotics by Product Segment - Penicillin, Cephalosporin, Macrolides, Quinolones, Carbapenems and Other Antibiotics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2006 (includes corresponding Graph/Chart).....II-871$350
   Table 36: Canadian 11-Year Perspective for Antibiotics by Product Segment - Percentage Breakdown of Dollar Sales for Penicillin, Cephalosporin, Macrolides, Quinolones, Carbapenems and Other Antibiotics Markets for Years 2005, 2010 & 2015 (includes corresponding Graph/Chart).....II-881$350
   A. Market Analysis.....II-89
Current and Future Analysis.....II-89
Key Players.....II-89
1$100
   B. Market Analytics.....II-90
Table 37: Japanese Recent Past, Current & Future Analysis for Antibiotics by Product Segment - Penicillin, Cephalosporin, Macrolides, Quinolones, Carbapenems and Other Antibiotics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).....II-90
1$350
   Table 38: Japanese Historic Review for Antibiotics by Product Segment - Penicillin, Cephalosporin, Macrolides, Quinolones, Carbapenems and Other Antibiotics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2006 (includes corresponding Graph/Chart).....II-911$350
   Table 39: Japanese 11-Year Perspective for Antibiotics by Product Segment - Percentage Breakdown of Dollar Sales for Penicillin, Cephalosporin, Macrolides, Quinolones, Carbapenems and Other Antibiotics Markets for Years 2005, 2010 & 2015 (includes corresponding Graph/Chart).....II-921$350
   A. Market Analysis.....II-93
Current and Future Analysis.....II-93
1$100
   B. Market Analytics.....II-94
Table 40: European Recent Past, Current & Future Analysis for Antibiotics by Geographic Region - France, Germany, Italy, UK, Spain, and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).....II-94
1$350
   Table 41: European Historic Review for Antibiotics by Geographic Region - France, Germany, Italy, UK, Spain, and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2006 (includes corresponding Graph/Chart).....II-951$350
   Table 42: European Recent Past, Current & Future Analysis for Antibiotics by Product Segment - Penicillin, Cephalosporin, Macrolides, Quinolones, Carbapenems and Other Antibiotics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).....II-961$350
   Table 43: European Historic Review for Antibiotics by Product Segment - Penicillin, Cephalosporin, Macrolides, Quinolones, Carbapenems and Other Antibiotics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2006 (includes corresponding Graph/Chart).....II-971$350
   Table 44: European 11-Year Perspective for Antibiotics by Geographic Region - Percentage Breakdown of Dollar Sales for France, Germany, Italy, UK, Spain, and Rest of Europe Markets for Years 2005, 2010 & 2015 (includes corresponding Graph/Chart).....II-981$350
   Table 45: European 11-Year Perspective for Antibiotics by Product Segment - Percentage Breakdown of Dollar Sales for Penicillin, Cephalosporin, Macrolides, Quinolones, Carbapenems and Other Antibiotics Markets for Years 2005, 2010 & 2015 (includes corresponding Graph/Chart).....II-991$350
   A. Market Analysis.....II-100
Current and Future Analysis.....II-100
Trends.....II-100
Over Consumption of Antibiotics – Cause of Concern.....II-100
Sanofi-Aventis SA – A Key Player.....II-100
1$100
   B. Market Analytics.....II-101
Table 46: French Recent Past, Current & Future Analysis for Antibiotics by Product Segment - Penicillin, Cephalosporin, Macrolides, Quinolones, Carbapenems and Other Antibiotics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).....II-101
1$350
   Table 47: French Historic Review for Antibiotics by Product Segment - Penicillin, Cephalosporin, Macrolides, Quinolones, Carbapenems and Other Antibiotics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2006 (includes corresponding Graph/Chart).....II-1021$350
   Table 48: French 11-Year Perspective for Antibiotics by Product Segment - Percentage Breakdown of Dollar Sales for Penicillin, Cephalosporin, Macrolides, Quinolones, Carbapenems and Other Antibiotics Markets for Years 2005, 2010 & 2015 (includes corresponding Graph/Chart).....II-1031$350
   A. Market Analysis.....II-104
Current and Future Analysis.....II-104
Bayer HealthCare AG – A Key Player.....II-104
1$100
   B. Market Analytics.....II-105
Table 49: German Recent Past, Current & Future Analysis for Antibiotics by Product Segment - Penicillin, Cephalosporin, Macrolides, Quinolones, Carbapenems and Other Antibiotics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).....II-105
1$350
   Table 50: German Historic Review for Antibiotics by Product Segment - Penicillin, Cephalosporin, Macrolides, Quinolones, Carbapenems and Other Antibiotics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2006 (includes corresponding Graph/Chart).....II-1061$350
   Table 51: German 11-Year Perspective for Antibiotics by Product Segment - Percentage Breakdown of Dollar Sales for Penicillin, Cephalosporin, Macrolides, Quinolones, Carbapenems and Other Antibiotics Markets for Years 2005, 2010 & 2015 (includes corresponding Graph/Chart).....II-1071$350
   A. Market Analysis.....II-108
Current and Future Analysis.....II-108
1$100
   B. Market Analytics.....II-109
Table 52: Italian Recent Past, Current & Future Analysis for Antibiotics by Product Segment - Penicillin, Cephalosporin, Macrolides, Quinolones, Carbapenems and Other Antibiotics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).....II-109
1$350
   Table 53: Italian Historic Review for Antibiotics by Product Segment - Penicillin, Cephalosporin, Macrolides, Quinolones, Carbapenems and Other Antibiotics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2006 (includes corresponding Graph/Chart).....II-1101$350
   Table 54: Italian 11-Year Perspective for Antibiotics by Product Segment - Percentage Breakdown of Dollar Sales for Penicillin, Cephalosporin, Macrolides, Quinolones, Carbapenems and Other Antibiotics Markets for Years 2005, 2010 & 2015 (includes corresponding Graph/Chart).....II-1111$350
   A. Market Analysis.....II-112
Current And Future Analysis.....II-112
GlaxoSmithKline Plc – A Key Player.....II-112
1$100
   B. Market Analytics.....II-113
Table 55: UK Recent Past, Current & Future Analysis for Antibiotics by Product Segment - Penicillin, Cephalosporin, Macrolides, Quinolones, Carbapenems and Other Antibiotics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).....II-113
1$350
   Table 56: UK Historic Review for Antibiotics by Product Segment - Penicillin, Cephalosporin, Macrolides, Quinolones, Carbapenems and Other Antibiotics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2006 (includes corresponding Graph/Chart).....II-1141$350
   Table 57: UK 11-Year Perspective for Antibiotics by Product Segment - Percentage Breakdown of Dollar Sales for Penicillin, Cephalosporin, Macrolides, Quinolones, Carbapenems and Other Antibiotics Markets for Years 2005, 2010 & 2015 (includes corresponding Graph/Chart).....II-1151$350
   Market Analysis.....II-116
Table 58: Spanish Recent Past, Current & Future Analysis for Antibiotics by Product Segment - Penicillin, Cephalosporin, Macrolides, Quinolones, Carbapenems and Other Antibiotics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).....II-116
1$350
   Table 59: Spanish Historic Review for Antibiotics by Product Segment - Penicillin, Cephalosporin, Macrolides, Quinolones, Carbapenems and Other Antibiotics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2006 (includes corresponding Graph/Chart).....II-1171$350
   Table 60: Spanish 11-Year Perspective for Antibiotics by Product Segment - Percentage Breakdown of Dollar Sales for Penicillin, Cephalosporin, Macrolides, Quinolones, Carbapenems and Other Antibiotics Markets for Years 2005, 2010 & 2015 (includes corresponding Graph/Chart).....II-1181$350
   A. Market Analysis.....II-119
Current and Future Analysis.....II-119
Poland.....II-119
Table 61: Polish Market for Antibiotics (2008): Percentage Breakdown of Market Share by Leading Companies - GSK Pharma, Bioton, Sandoz Corp, Ranbaxy and Others (includes corresponding Graph/Chart).....II-119
Focus on Select Players.....II-119
1$350
   B. Market Analytics.....II-120
Table 62: Rest of Europe Recent Past, Current & Future Analysis for Antibiotics by Product Segment - Penicillin, Cephalosporin, Macrolides, Quinolones, Carbapenems and Other Antibiotics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).....II-120
1$350
   Table 63: Rest of Europe Historic Review for Antibiotics by Product Segment - Penicillin, Cephalosporin, Macrolides, Quinolones, Carbapenems and Other Antibiotics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2006 (includes corresponding Graph/Chart).....II-1211$350
   Table 64: Rest of Europe 11-Year Perspective for Antibiotics by Product Segment - Percentage Breakdown of Dollar Sales for Penicillin, Cephalosporin, Macrolides, Quinolones, Carbapenems and Other Antibiotics Markets for Years 2005, 2010 & 2015 (includes corresponding Graph/Chart).....II-1221$350
   A. Market Analysis.....II-123
Current and Future Analysis.....II-123
India.....II-123
Rising Prices of Penicillin G to Affect Antibiotics Production.....II-123
Market for Injectable Antibiotics Poised to Grow.....II-123
1$100
   Cipla, Pharmaceutical Market Leader in 2009.....II-124
China.....II-124
Carbapenem Witnesses Robust Growth in China.....II-124
Key Players.....II-124
1$100
   Ranbaxy Laboratories Ltd. (India).....II-1251$100
   B. Market Analytics.....II-126
Table 65: Asia-Pacific Recent Past, Current & Future Analysis for Antibiotics by Product Segment - Penicillin, Cephalosporin, Macrolides, Quinolones, Carbapenems and Other Antibiotics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).....II-126
1$350
   Table 66: Asia-Pacific Historic Review for Antibiotics by Product Segment - Penicillin, Cephalosporin, Macrolides, Quinolones, Carbapenems and Other Antibiotics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2006 (includes corresponding Graph/Chart).....II-1271$350
   Table 67: Asia-Pacific 11-Year Perspective for Antibiotics by Product Segment - Percentage Breakdown of Dollar Sales for Penicillin, Cephalosporin, Macrolides, Quinolones, Carbapenems and Other Antibiotics Markets for Years 2005, 2010 & 2015 (includes corresponding Graph/Chart).....II-1281$350
   A. Market Analysis.....II-129
Current and Future Analysis.....II-129
1$100
   B. Market Analytics.....II-130
Table 68: Rest of World Recent Past, Current & Future Analysis for Antibiotics by Product Segment - Penicillin, Cephalosporin, Macrolides, Quinolones, Carbapenems and Other Antibiotics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).....II-130
1$350
   Table 69: Rest of World Historic Review for Antibiotics by Product Segment - Penicillin, Cephalosporin, Macrolides, Quinolones, Carbapenems and Other Antibiotics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2006 (includes corresponding Graph/Chart).....II-1311$350
   Table 70: Rest of World 11-Year Perspective for Antibiotics by Product Segment - Percentage Breakdown of Dollar Sales for Penicillin, Cephalosporin, Macrolides, Quinolones, Carbapenems and Other Antibiotics Markets for Years 2005, 2010 & 2015 (includes corresponding Graph/Chart).....II-1321$350
    
 
 


Sales queries: Sales@StrategyR.com
Research queries: Info411@StrategyR.com